adrenal gland disease: A disease involving the adrenal gland.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
222 |
4. Check minimum number of eventsNone |
222 |
5. Include endpointsNone |
222 |
6. Filter based on genotype QC (FinnGen only) |
209 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E27
- Name in latin
- Alia hyperfunctio adrenocorticalis
Similar endpoints
↥List of similar endpoints to
Other adrenocortical overactivity
based on the number of shared cases.
Similar with more cases:
- Other disorders of adrenal gland
- Exclusions for E4_PCOS_BROAD
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4574 | 3566 | 1002 |
| Only index persons | 3335 | 2615 | 720 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.09 | 0.10 | 0.03 |
| Only index persons | 0.08 | 0.10 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 7.91 | 7.69 | 8.52 |
| Only index persons | 8.08 | 7.85 | 8.90 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 209 | 174 | 35 |
| Unadjusted period prevalence (%) | 0.05 | 0.06 | 0.02 |
| Median age at first event (years) | 16.47 | 8.46 | 56.25 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 222
- Matched controls
- 2220
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E27.0
ICD-10 Finland
Other adrenocortical overactivity
9431.9
274.8
205
*
H02AB09
ATC
hydrocortisone; systemic
29.4
82.7
59
27
NK6MA
NOMESCO Finland
Measurement of bone age from hand and elbow using X-ray
14.6
37.6
36
29
105
Kela drug reimbursment
Adrenal cortical hypofunction
+∞
29.9
28
*
E27.1
ICD-10 Finland
Primary adrenocortical insufficiency
+∞
26.6
25
*
H02AA02
ATC
fludrocortisone; oral
89.4
22.1
24
*
E27.4
ICD-10 Finland
Other and unspecified adrenocortical insufficiency
+∞
18.0
17
*
D44.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Adrenal gland
194.9
17.8
18
*
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
8.6
17.8
24
31
E30.1
ICD-10 Finland
Precocious puberty
183.2
16.7
17
*
BCA31
NOMESCO Finland
Endoscopic unilateral adrenalectomy
+∞
15.8
15
*
25508
ICD-8 Finland
Diseases of adrenal glands, Hyperfunctio adrenocorticalis alia
+∞
13.7
13
*
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
5.3
11.7
25
52
G47.3
ICD-10 Finland
Sleep apnoea
3.6
11.1
41
131
D35.0
ICD-10 Finland
Benign neoplasm: Adrenal gland
115.2
10.5
11
*
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
42.1
10.1
12
*
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
104.3
9.5
10
*
E24.9
ICD-10 Finland
Cushing syndrome, unspecified
+∞
9.4
9
*
H02AB07
ATC
prednisone; oral
3.7
8.5
29
87
L68.0
ICD-10 Finland
Hirsutism
93.5
8.5
9
*
E24.0
ICD-10 Finland
Pituitary-dependent Cushing disease
+∞
8.4
8
*
E24.8
ICD-10 Finland
Other Cushing syndrome
+∞
8.4
8
*
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
+∞
8.4
8
*
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.5
8.3
69
342
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.6
8.2
57
259
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.1
7.9
35
125
C03CA01
ATC
furosemide; systemic
3.0
7.8
39
149
H03AA01
ATC
levothyroxine sodium; systemic
2.6
7.8
51
225
E66.01
ICD-10 Finland
Obesity due to excess calories
3.1
7.4
33
118
E89.6
ICD-10 Finland
Postprocedural adrenocortical(-medullary) hypofunction
+∞
7.3
7
*
Z51.80
ICD-10 Finland
Manipulation of puberty development with hormone therapy
+∞
7.3
7
*
WX002
NOMESCO Finland
Sedation and analgesia
2.8
7.2
41
168
EP1AE
NOMESCO Finland
Neck ultrasound examination
4.4
7.0
18
44
B01AB05
ATC
enoxaparin; parenteral
2.5
6.9
53
251
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
3.2
6.8
28
95
E34.45
ICD-10 Finland
Abnormal growth increase
71.8
6.5
7
*
M01AH01
ATC
celecoxib; oral
3.2
6.4
26
88
M05BA04
ATC
alendronic acid; oral
6.6
6.3
15
24
E27.5
ICD-10 Finland
Adrenomedullary hyperfunction
+∞
6.3
6
*
E27.2
ICD-10 Finland
Addisonian crisis
+∞
6.3
6
*
E30.8
ICD-10 Finland
Other disorders of puberty
+∞
6.3
6
*
E22.80
ICD-10 Finland
Central precocious puberty
+∞
6.3
6
*
J01FF01
ATC
clindamycin; systemic
2.3
6.3
53
262
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.7
6.2
20
58
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
38
66
6.74
21.85
3.1
1.9
3.93
8.04
nmol/l
2.34
33
60
41
97
4.96
16.80
2.2
1.5
10.64
7.77
u/l
0.47
22
64
42
108
4.56
15.51
2.0
1.5
15.60
15.90
iu/l
0.02
22
78
15
6
26.63
11.29
1.4
1.0
236.27
71.00
nmol/24h
—
15
6
19
21
9.78
9.74
2.2
1.7
0.10
0.21
nmol/l
0.85
14
16
16
42
4.03
5.64
1.3
1.2
—
—
—
0
0
74
450
1.97
5.04
5.0
3.0
2.35
2.37
mmol/l
0.96
66
398
102
699
1.85
4.77
3.6
2.6
72.78
71.27
nmol/l
0.22
95
630
44
232
2.12
4.37
2.8
1.9
—
—
—
0
0
194
1674
2.26
4.07
6.0
4.2
1.91
1.83
mu/l
0.44
182
1556
33
160
2.25
4.02
2.8
1.8
—
—
—
0
0
32
157
2.21
3.79
2.8
1.8
—
—
—
0
0
103
745
1.71
3.76
11.4
7.8
1.22
1.22
mmol/l
0.24
91
664
74
493
1.75
3.60
1.9
1.6
91.59
96.24
pmol/l
0.38
41
251
172
1446
1.84
3.55
5.7
3.7
14.29
14.33
pmol/l
0.07
156
1316
6
6
10.23
3.51
2.3
1.0
75.50
74.83
%
—
6
6
6
6
10.23
3.51
2.3
1.0
478.83
309.17
mu/l
—
6
6
97
706
1.66
3.37
7.5
5.9
12.13
12.94
umol/l
0.10
91
658
14
50
2.92
3.15
1.6
1.4
—
—
—
0
0
14
50
2.92
3.15
1.6
1.4
—
—
—
0
0
21
93
2.39
3.14
11.9
2.6
1.22
1.23
mmol/l
1.06
21
84
15
57
2.75
3.03
1.7
1.2
—
—
—
0
0
30
157
2.05
3.03
10.5
7.2
105.27
104.85
mmol/l
0.21
30
157
8
17
4.84
2.94
1.9
1.8
—
—
—
0
0
53
340
1.73
2.88
2.5
3.1
1.00
1.63
mg/l
0.75
35
236
15
59
2.65
2.85
1.7
1.2
—
—
—
0
0
11
34
3.35
2.77
1.5
1.3
—
—
—
0
0
33
185
1.92
2.76
1.2
1.3
364.41
123.99
iu/ml
—
8
70
60
406
1.65
2.67
3.0
2.3
—
—
—
0
0
23
116
2.10
2.56
7.9
7.5
5.46
5.20
kpa
0.49
23
111
23
116
2.10
2.56
8.0
7.5
13.99
14.12
kpa
0.02
23
111
58
393
1.64
2.56
3.4
3.1
35.17
34.28
ng/l
0.02
36
199
35
207
1.82
2.49
8.1
6.3
2.02
0.66
mmol/l
2.11
27
157
134
1105
1.54
2.48
10.2
8.2
4.34
3.85
e9/l
1.82
117
939
165
1427
1.61
2.46
3.9
3.2
5.62
5.57
mmol/l
0.18
153
1306
83
619
1.54
2.44
4.9
3.3
—
—
—
0
0
8
22
3.73
2.38
1.9
1.6
—
—
—
0
0
72
523
1.56
2.37
4.9
3.2
0.26
0.31
e6/l
0.18
58
383
40
252
1.72
2.31
3.8
4.3
851.11
797.93
ng/l
0.06
33
202
18
86
2.19
2.30
3.0
1.7
—
—
—
0
0
8
23
3.57
2.29
2.0
1.7
—
—
—
0
0
134
1118
1.50
2.25
10.9
6.0
91.36
86.68
u/l
0.34
127
1041
22
117
1.98
2.15
8.2
7.5
-0.19
0.99
mmol/l
0.73
17
89
33
201
1.75
2.14
3.4
2.5
2.46
2.43
mmol/l
0.81
28
166
14
280
0.47
2.09
1.6
1.5
—
—
—
0
0
25
141
1.87
2.07
1.7
1.3
173.21
383.78
u/ml
0.63
25
133
6
15
4.08
2.05
1.3
1.9
—
—
—
0
0
6
15
4.08
2.05
1.3
1.9
—
—
—
0
0
6
15
4.08
2.05
1.3
1.9
—
—
—
0
0
9
33
2.80
1.95
2.0
1.6
—
—
—
0
0
5
11
4.62
1.95
1.0
1.0
—
—
—
0
0
22
122
1.89
1.92
1.3
1.3
288.68
293.56
miu/ml
—
10
60
150
1302
1.47
1.92
3.5
3.1
1.29
1.17
mmol/l
1.29
142
1220
15
72
2.16
1.91
1.7
1.3
—
—
—
0
0
9
34
2.72
1.88
1.8
1.3
—
—
—
0
0
126
1061
1.43
1.88
3.2
3.0
37.40
31.03
u/l
0.69
121
1012
140
1212
1.42
1.73
5.5
4.1
38.02
38.18
mmol/mol
0.07
133
1138
6
146
0.39
1.72
1.2
1.6
—
—
—
0
0
64
487
1.44
1.62
2.3
2.4
2.66
2.76
mg/l
0.17
59
417
14
71
2.04
1.57
2.6
1.6
—
—
—
0
0
5
15
3.38
1.53
1.4
1.4
—
—
—
0
0
5
15
3.38
1.53
1.4
1.4
—
—
—
0
0
5
15
3.38
1.53
1.4
1.4
—
—
—
0
0
5
15
3.38
1.53
1.4
1.4
—
—
—
0
0
6
21
2.91
1.51
1.0
1.2
—
—
—
0
0
6
21
2.91
1.51
1.2
1.1
—
—
—
0
0
6
21
2.91
1.51
1.3
2.0
—
—
—
0
0
5
16
3.17
1.44
1.4
1.4
—
—
—
0
0
5
16
3.17
1.44
1.4
1.4
—
—
—
0
0
5
16
3.17
1.44
1.2
2.4
—
—
—
0
0
9
41
2.24
1.38
1.4
1.8
—
—
—
0
0
9
41
2.24
1.38
1.4
1.8
—
—
—
0
0
11
54
2.09
1.35
1.6
1.3
—
—
—
0
0
140
1241
1.35
1.32
5.3
3.9
—
249.65
—
0
17
152
1365
1.36
1.31
3.8
3.3
1.43
1.49
mmol/l
0.86
144
1277
8
35
2.33
1.28
1.1
1.0
—
—
—
0
0
153
1381
1.35
1.24
4.0
3.3
4.43
4.55
mmol/l
1.02
147
1300
10
49
2.09
1.24
2.7
1.8
—
—
—
0
0
105
900
1.32
1.22
6.5
4.7
0.00
0.00
estimate
-0.00
22
188
30
208
1.51
1.21
3.9
2.5
2.31
2.53
g/l
1.43
30
189
14
79
1.82
1.20
1.3
1.4
—
—
—
0
0
153
1386
1.33
1.18
4.2
3.6
2.61
2.71
mmol/l
0.89
146
1293
5
114
0.43
1.16
1.2
1.5
—
—
—
0
0
33
236
1.47
1.15
3.4
6.0
30.45
30.27
s
0.09
33
230
11
58
1.94
1.14
1.4
1.9
—
—
—
0
0
105
907
1.30
1.13
5.0
3.4
0.00
0.00
estimate
-0.00
22
183
8
41
1.99
1.10
5.6
3.4
53.88
54.56
%
—
8
41
39
292
1.41
1.08
5.4
3.8
14.18
15.72
mg/mmol
0.08
29
202
183
1713
1.39
1.06
21.9
13.1
14.24
13.83
%
0.59
176
1683
5
22
2.30
1.04
1.2
1.5
—
—
—
0
0
65
532
1.31
1.03
6.8
8.1
1.17
1.11
inr
0.25
24
167
7
131
0.52
1.02
1.4
1.7
—
—
—
0
0
32
234
1.43
1.01
1.5
1.6
1.53
1.37
%
0.68
27
212
14
84
1.71
1.00
2.0
2.7
62.00
84.24
ml/min/173m2
—
7
34
9
49
1.87
1.00
2.9
1.9
—
—
—
0
0
193
1828
1.43
0.99
20.0
10.6
21.51
22.36
mg/l
0.16
153
1344
33
244
1.41
0.98
5.7
6.6
1.48
1.34
mmol/l
0.16
23
198
59
480
1.31
0.97
5.9
3.3
0.14
0.00
estimate
0.48
22
188
7
37
1.92
0.95
1.3
1.3
—
—
—
0
0
6
27
2.26
0.94
1.3
1.1
—
—
—
0
0
11
63
1.78
0.92
2.2
2.3
—
—
—
0
0
6
29
2.10
0.90
1.5
1.7
—
—
—
0
0
48
590
0.76
0.89
2.1
2.4
—
—
—
0
0
31
231
1.40
0.89
3.9
2.5
12.36
14.10
umol/l
0.61
31
219
41
321
1.34
0.88
3.2
3.0
2.24
4.39
e6/l
1.19
21
164
103
909
1.25
0.87
5.0
3.3
0.00
0.00
estimate
-0.00
22
193
6
30
2.03
0.87
1.3
1.8
—
—
—
0
0
6
30
2.03
0.87
1.3
1.8
—
—
—
0
0
12
72
1.70
0.87
13.4
9.0
95.70
94.90
%
0.55
12
72
149
1373
1.26
0.85
19.3
8.5
94.99
97.38
ml/min/173m2
0.44
123
1035
87
758
1.24
0.82
2.5
2.0
—
—
—
0
0
25
183
1.41
0.80
9.4
6.5
24.49
24.03
mmol/l
0.26
25
183
139
1277
1.24
0.79
5.0
3.7
12.65
8.92
mm/h
2.21
130
1171
41
327
1.31
0.78
3.2
2.9
1.28
0.99
e6/l
0.19
21
167
15
99
1.55
0.78
1.3
1.5
—
—
—
0
0
10
60
1.70
0.73
2.1
2.1
—
—
—
0
0
30
231
1.35
0.72
11.9
9.8
24.50
24.76
mmol/l
0.16
30
231
5
27
1.87
0.69
3.8
1.7
—
—
—
0
0
32
252
1.32
0.67
2.7
2.3
3707.34
6036.81
u/l
0.26
12
99
78
687
1.21
0.64
1.6
1.7
0.94
2.89
u/ml
1.53
16
157
32
258
1.28
0.58
1.3
1.3
1.40
9.82
u/ml
—
8
104
75
665
1.19
0.57
5.3
3.3
—
—
—
0
0
16
116
1.41
0.56
3.1
2.5
—
—
—
0
0
6
38
1.59
0.54
4.0
1.9
—
—
—
0
0
54
620
0.83
0.54
2.5
2.6
—
—
—
0
0
7
45
1.57
0.49
1.7
1.9
—
—
—
0
0
48
415
1.20
0.48
4.0
3.1
1.02
1.02
kg/l
0.81
12
58
29
239
1.25
0.45
3.8
3.0
171.75
268.66
ng/l
0.26
16
135
13
96
1.38
0.42
13.1
11.3
1.17
1.04
mg/l
0.45
13
89
34
398
0.83
0.42
1.6
1.5
—
—
—
0
0
22
177
1.27
0.42
1.8
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
127.23
—
0
15
0
16
0.00
0.41
0.0
1.0
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
88
812
1.14
0.39
3.2
2.6
—
—
—
0
0
0
19
0.00
0.39
0.0
1.1
—
—
—
0
0
0
19
0.00
0.39
0.0
1.2
—
—
—
0
0
9
69
1.32
0.37
1.3
1.5
—
—
—
0
0
14
179
0.77
0.37
1.6
1.4
—
—
—
0
0
12
90
1.35
0.36
1.1
1.7
—
—
—
0
0
10
73
1.39
0.35
1.5
1.6
—
—
—
0
0
6
45
1.34
0.34
1.2
1.9
—
—
—
0
0
6
46
1.31
0.33
1.2
1.1
—
—
—
0
0
30
258
1.19
0.33
1.3
1.3
47.58
19.56
iu/ml
—
8
69
39
439
0.86
0.32
2.4
2.0
—
—
—
0
0
10
75
1.35
0.30
1.5
1.6
—
105.71
—
0
7
12
93
1.31
0.30
1.1
1.2
—
—
—
0
0
12
93
1.31
0.30
1.6
1.6
—
—
—
0
0
33
370
0.87
0.26
2.2
1.9
—
—
—
0
0
211
2084
1.25
0.24
26.4
15.5
269.15
265.06
e9/l
0.42
205
2017
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
0.98
—
0
8
211
2088
1.21
0.19
26.5
15.5
40.01
39.34
%
1.32
206
1997
7
59
1.19
0.18
3.0
2.5
0.62
0.51
nmol/l
—
7
50
211
2090
1.19
0.16
26.3
15.4
4.56
4.49
e12/l
1.31
203
2016
13
151
0.85
0.16
1.5
1.5
—
—
—
0
0
8
73
1.10
0.16
1.0
1.2
—
—
—
0
0
11
127
0.86
0.12
1.5
1.4
—
—
—
0
0
11
127
0.86
0.12
1.5
1.4
—
—
—
0
0
11
127
0.86
0.12
1.5
1.4
—
—
—
0
0
11
127
0.86
0.12
1.5
1.4
—
—
—
0
0
10
85
1.18
0.12
1.2
1.4
—
—
—
0
0
19
173
1.11
0.11
6.4
5.2
4.80
1.92
ug/l
0.50
19
149
170
1685
1.04
0.05
4.6
4.0
—
—
—
0
0
12
130
0.92
0.04
5.1
5.2
28.50
22.74
%
—
7
66
22
210
1.05
0.04
1.0
1.1
—
—
—
0
0
20
201
0.99
0.00
2.1
1.8
—
—
—
0
0
13
133
0.98
0.00
9.0
4.9
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
8
81
0.99
-0.00
1.0
1.1
—
10.32
—
0
16
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
17
170
1.00
-0.00
1.1
1.5
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_ADREACT and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_ADREACT | 4.569 [3.1, 6.73] | < 0.001 |
| Birth year | 0.992 [0.98, 1.0] | 0.084 |
During the follow-up period (1.1.1998 — 31.12.2019), 65 out of 2952 females with E4_ADREACT died.
Males
No dataMortality risk
Mortality risk for people of age
years, who have E4_ADREACT.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.47% | No data |
| 5 | 2.272% | No data |
| 10 | 5.762% | No data |
| 15 | 11.548% | No data |
| 20 | 18.618% | No data |
Relationships between endpoints
↥Index endpoint: E4_ADREACT – Other adrenocortical overactivity
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data